Analysts Expect Obseva SA (OBSV) to Announce ($0.35) Earnings Per Share
Shares of Obseva SA (NASDAQ:OBSV) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1-year consensus target price of $21.00 for the company and are forecasting that the company will post ($0.35) earnings per share for the current quarter, according to Zacks. Zacks has also given Obseva SA an industry rank of 102 out of 265 based on the ratings given to related companies.
A number of equities analysts recently issued reports on the company. Jefferies Group LLC assumed coverage on Obseva SA in a research note on Tuesday, February 21st. They issued a “buy” rating and a $21.00 target price for the company. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $27.00 price target on shares of Obseva SA in a research report on Tuesday. Finally, Leerink Swann assumed coverage on Obseva SA in a research report on Tuesday, February 21st. They set an “outperform” rating and a $21.00 price target on the stock.
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/04/20/analysts-expect-obseva-sa-obsv-to-announce-0-35-earnings-per-share.html
Obseva SA (NASDAQ:OBSV) opened at 7.11 on Thursday. Obseva SA has a 1-year low of $7.01 and a 1-year high of $14.69. The stock’s market cap is $28.93 million. The stock has a 50 day moving average price of $10.79 and a 200 day moving average price of $11.46.
Obseva SA Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Obseva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva SA and related companies with MarketBeat.com's FREE daily email newsletter.